The median onset of AEs associated with MEK retinopathy in this study was 1.5–4.0 days and, consistent with previous reports, prompt recovery or improvement was achieved with either treatment discontinuation, interruption or dose reduction. Here, MAP2K7 is linked to retinal disorder.